Sign In
Buy FSNUY
$11.30
+0.0300 (+0.266%)
At Close: Jun 22, 2026
Fresenius SE & Co. KGaA (FSNUF) Q2 2023 Earnings Call Transcript
06:27pm, Friday, 04'th Aug 2023
Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q2 2023 Earnings Conference Call August 2, 2023 7:30 AM ET Company Participants Markus Georgi - Senior Vice President of Investor Relations Michael Sen - Chief Ex
Fresenius: 90%+ Upside At This Time
05:24am, Sunday, 09'th Jul 2023
Fresenius, a German healthcare company, is highlighted as a promising investment due to its global presence, market leadership, and potential for significant growth in the coming years. Despite underp
Fresenius launches biosimilar version of AbbVie's Humira at 5% discount
10:59am, Monday, 03'rd Jul 2023
The generic drug unit of Germany's Fresenius said on Monday the price for Idacio, its copycat version of Abbvie's top-selling rheumatoid arthritis drug, will be at a 5% discount to Humira's list price
Fresenius: Still Struggling, Still Undervalued
07:22am, Sunday, 23'rd Apr 2023
Fresenius: Still Struggling, Still Undervalued.
My Dividend Stock Portfolio: New All-Time Dividend Record - 99 Holdings With 25 Buys
10:00am, Wednesday, 12'th Apr 2023
Inflation and (expected) actions by the Federal Reserve continue to dominate market movements even though the turmoil in the financial sector shortly took center stage. Markets have started the new ye
Fresenius SE & Co. KGaA (FSNUF) Q4 2022 Earnings Call Transcript
07:41pm, Wednesday, 22'nd Feb 2023
Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q4 2022 Results Conference Call February 22, 2023 7:30 AM ET Company Participants Markus Georgi - Senior Vice President-Investor Relations Michael Sen - Chief Exe
Fresenius: One-Off Special Situation Opportunity To Buy
03:48am, Tuesday, 14'th Feb 2023
Over the last six months, Fresenius has seen the exit of its CEO, increasing activist exposure, and is reviewing the deconsolidation of its largest subsidiary Fresenius Medical Care. We view this deco
Fresenius: Maximum Pessimism Reached, Potential Triple-Digit 3-Year Rate Of Return
09:14am, Saturday, 03'rd Dec 2022
I've been buying Fresenius in small portions and adding to my position again and again over the past year. It's now more than 3% of my portfolio. While this company remains a long-term turnaround play
Fresenius SE: A Buy After Quarterly Results
06:53am, Tuesday, 01'st Nov 2022
Fresenius SE is reporting mediocre results once again with Fresenius Medical Care struggling due to labor shortage and macroeconomic challenges. While Fresenius Medical Care and Fresenius Kabi are str
Fresenius SE & Co. KGaA (FSNUF) Q3 2022 Earnings Call Transcript
01:50pm, Monday, 31'st Oct 2022
Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q3 2022 Earnings Conference Call October 31, 2022 8:30 AM ET Company Participants Markus Georgi – Senior Vice President-Investor Relations Michael Sen – Chief
Fresenius - No One Likes A Contrarian During A Downturn
01:50am, Sunday, 25'th Sep 2022
I've received plenty of inquiries with regards to Fresenius and its somewhat terrible performance YTD so far. Readers are asking if I'm "out" the company, or if I continue to believe that this company
Fresenius SE CEO to quit after earnings outlook sours
01:44pm, Friday, 19'th Aug 2022
FRANKFURT (Reuters) -Fresenius SE said its long-serving Chief Executive Stephan Sturm would quit, to be replaced by the head of its drugs unit, after the diversified group's earnings were hit followin
Fresenius: Too Cheap, Measured By Sum-Of-The-Parts
06:30pm, Thursday, 18'th Aug 2022
The shares of Fresenius, one of the world's largest healthcare groups, have been in a downward and then a sideways trend since 2017. Corona pandemic has been a major challenge, especially for its subs
Fresenius SE & Co. KGaA (FSNUF) CEO Stephan Sturm on Q2 2022 Results - Earnings Call Transcript
03:54pm, Wednesday, 03'rd Aug 2022
Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q2 2022 Earnings Conference Call July 28, 2022 7:30 AM ET Company Participants Markus Georgi - Senior Vice President of Investor Relations Stephan Sturm - Preside
Fresenius: Revisiting The Thesis - Still A Buy
03:44am, Sunday, 19'th Jun 2022
We'll take a look at Fresenius in order to determine if the company still represents a good investment opportunity. Given a recent share price weakness, it's not strange that some investors are wonder
